MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer

Nikpour, Mahnaz; Emadi‐Baygi, Modjtaba; Fischer, Ute; Niegisch, Günter; Schulz, Wolfgang A.; Nikpour, Parvaneh

doi:10.1016/j.urolonc.2013.11.005

Cited by 22 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed a significant difference of MTDH expression between bladder benign specimens and cancers (19). This result was also proved by another study by detection of MTDH mRNA expression in bladder benign and cancer samples (31), and MTDH expression has also been verified in 17 bladder cancer cell lines (31). RT112 cell lines have the highest expression, which is higher than that of DU145 and LNCaP as the controls, whereas HT1376 showed the lowest expression in the 17 cell lines (31).…”

Section: Progression and Survival Of Mtdh In Prostate Cancersupporting

confidence: 58%

“…Regarding MTDH and progression of bladder cancer, conflicting conclusions were reported in two studies (19,31) possibly due to their limited samples. Secondly, follow-up times and repeated studies are required to investigate the higher expression of MTDH as an influence of prognostic factors.…”

Section: Progression and Survival Of Mtdh In Prostate Cancermentioning

confidence: 98%

“…The study by Nikpour et al (31) also confirmed that MTDH promoted bladder cancer cell survival, clonogenicity and migration, which were verified by downregulation of MTDH via small interfering RNA. In addition to increased apoptosis, reductions of cell viability and migration have also been observed in bladder cancer (31).…”

Section: Progression and Survival Of Mtdh In Prostate Cancermentioning

confidence: 99%

See 2 more Smart Citations

Metadherin in prostate, bladder, and kidney cancer: A systematic review

Zhao

Wei

Gao

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Metadherin (MTDH) has been identified as an important oncogene in carcinogenesis, tumor progression and metastasis in numerous malignancies, through signal transduction pathways. MTDH is a potential biomarker and therapeutic target in cancers. The present systematic review was performed to search for studies regarding MTDH and prostate, bladder and kidney cancer using several databases and the eligible studies were reviewed. MTDH expression was found to significantly increase in prostate, bladder and kidney cancers, not only in clinical tissue samples, but also in cancer cell lines. Reviewing the clinical and statistical analysis revealed that MTDH may be involved in urologic cancer progression, metastasis and prognosis. MTDH may be an independent or one of the cofactors in urologic cancers for prediction of patient survival, and may be involved in potential anticancer strategies. MTDH may be associated with several signal transduction pathways in urologic cancers, indicating latent targets to develop anticancer therapeutic strategy. Further studies are required to confirm these findings. IntroductionMetadherin (MTDH), also known as astrocyte-elevated gene (AEG)-1 and lysine-rich CEACAM-1-associated protein (LYRIC) (1-2), was first identified in human fetal astrocytes induced by human immunodeficiency virus-1 in 2002 (3). MTDH has been cloned for nearly ten years (4-6) and is considered to be an important oncogene in carcinogenesis, tumor progression and metastasis, via a series of signaling pathways (7-9). However, as the exact functions of MTDH in cancer remain unclear, particularly in malignant tumors, future investigations are required (10).Recent studies have shown that high expressions of MTDH are present in various tumors, involving the nervous, urogenital, respiratory and digestive systems (9,(11)(12)(13)(14)(15)(16)(17)(18)(19). Evidence indicates that MTDH knockdown significantly inhibited the growth of gastric cancer cells (9). MTDH is an anti-apoptotic gene in glioma cells and could be used as a target of microRNA-136 in anticancer therapeutic strategy (11). A study revealed that MTDH promotes invasion and metastasis through the activation of nuclear factor-κB (NF-κB), interleukin-8 and matrix metalloproteinase-9 in breast cancer (12), which is consistent with studies in non-small cell lung cancer and glioma (13,14). MTDH has been shown to be associated with a poor prognosis in malignancies, including non-small cell lung cancer, invasive breast cancer, laryngeal squamous cell carcinoma, gallbladder adenocarcinoma, tongue carcinoma and bladder cancer (15)(16)(17)(18)(19). MTDH is also associated with the prognosis of carcinoma, possibly due to chemoresistance and radiosensitivity in cancer therapy (20,21).Increasing evidence indicates that MTDH is an important mediator in signal transduction pathways in malignancies, a potential biomarker to predict cancer survival and provides information to develop target chemotherapies. The present systematic review aimed to investigate the expression, pa...

show abstract

Section: Progression and Survival Of Mtdh In Prostate Cancersupporting

confidence: 58%

Section: Progression and Survival Of Mtdh In Prostate Cancermentioning

confidence: 98%

Section: Progression and Survival Of Mtdh In Prostate Cancermentioning

confidence: 99%

See 1 more Smart Citation

Metadherin in prostate, bladder, and kidney cancer: A systematic review

Zhao

Wei

Gao

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Additionally, opening of mitochondrial transition pores, an indicator of cell death, is enhanced in tissues of aged mice (Mather and Rottenberg, 2000). In contrast, downregulation of AEG-1 increased caspase 3/7 activities and reduced mitochondrial potential disruption and cell survival (Nikpour et al , 2014). More investigations are clearly needed to better understand the role of AEG-1 in regulating ROS-mediated mitochondrial dysfunctions that could supplement potential impact of AEG-1 in aging and related diseases.…”

Section: Astrocytes and Aeg-1 In Agingmentioning

confidence: 99%

Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND

Vartak-Sharma

Nooka

Ghorpade

2017

Progress in Neurobiology

View full text Add to dashboard Cite

Recent attempts to analyze human immunodeficiency virus (HIV)-1-induced gene expression changes in astrocytes uncovered a multifunctional oncogene, astrocyte elevated gene-1 (AEG-1). Our previous studies revealed that AEG-1 regulates reactive astrocytes proliferation, migration and inflammation, all hallmarks of aging and CNS injury. Moreover, the involvement of AEG-1 in neurodegenerative disorders, such as Huntington’s disease and migraine, and its induction in the aged brain suggest a plausible role in regulating overall CNS homeostasis and aging. Therefore, it is important to investigate AEG-1 specifically in aging-associated cognitive decline. In this study, we decipher the common mechanistic links in cancer, aging and HIV-1-associated neurocognitive disorders that likely contribute to AEG-1-based regulation of astrocyte responses and function. Despite AEG-1 incorporation into HIV-1 virions and its induction by HIV-1, tumor necrosis factor-α and interleukin-1β, the specific role(s) of AEG-1 in astrocyte-driven HIV-1 neuropathogenesis are incompletely defined. We propose that AEG-1 plays a central role in a multitude of cellular stress responses involving mitochondria, endoplasmic reticulum and the nucleolus. It is thus important to further investigate AEG-1-based cellular and molecular regulation in order to successfully develop better therapeutic approaches that target AEG-1 to combat cancer, HIV-1 and aging.

show abstract

“…Angiogenic markers such as Ang-1, CD31 and HIF1 alpha are correlated with AEG-1 up-regulation in tumors formed by AEG-1-transduced rat embryo fibroblasts. Nikpour et al showed the overexpression of AEG-1 in bladder cancer and they reported AEG-1 protects apoptosis and defects in apoptosis are familiar to contribute substantially to chemoresistance of bladder cancer, the protein may constitute a valid target for overcoming therapy resistance 43 .…”

Section: Fig 1: Various Biological Functions and Potential Lead Molementioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

AEG-1 expression is known to elevate in diverse cancers, where it plays a primary role in activating multiple signaling pathways that drives copious oncogenic properties. The versatile role of AEG-1 in mediating oncogenesis was found to be cognate with numerous signaling cascades such as the activation of NF-κB/p65, Ha-Ras, PI3K/Akt, ERK/MAPK, Wnt/β-catenin, AURKA and RNAi pathways. In addition, recent clinical studies reveal that AEG-1 interaction with SND1/AGO2 in RISC may stimulate oncogenic transformation. The defeat of AEG-1 leads to PARP cleavage catalyzed by caspase-3, a key process in mediating apoptosis in AEG-1 expressed cancer cells. Moreover, AEG-1 confers chemo-résistance of cancer cells by inducing autophagy. In recent past, there are several studies reveal that AEG-1 down regulation inhibits chemo-resistance and oncogenic properties of various cancers. With this background, this review will address the multifaceted role of AEG-1 as oncogene and stipulating its potential to become a new therapeutic target and prognostic biomarker for the treatment of cancer.

show abstract

MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer

Cited by 22 publications

References 29 publications

Metadherin in prostate, bladder, and kidney cancer: A systematic review

Metadherin in prostate, bladder, and kidney cancer: A systematic review

Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND

Untitled

Contact Info

Product

Resources

About